A systematic review of the effectiveness of adalimumab

More documents

Recommendations

Info

216 Appendix 10 TABLE 149 Variation 14: TNF inhibitors last (20,000 patients) Option Cost (£) QSE QALYs QSE Adal 37,360 214 1.8689 0.0219 Etan 49,845 262 2.9910 0.0267 Adal+MTX 37,334 215 2.1633 0.0223 Etan+MTX 50,136 263 2.9875 0.0272 Infl+MTX 37,314 208 1.9216 0.0226 Base 2,869 11 1.0236 0.0183 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 34,491 213 0.8453 0.0160 Etan – Base 46,976 259 1.9675 0.0229 Ad+M – Base 34,465 213 1.1398 0.0171 Et+M – Base 47,267 260 1.9639 0.0234 In+M – Base 34,445 206 0.8980 0.0170 Adal – Ad+M 26 292 –0.2945 0.0204 Et+M – Etan 291 348 –0.0035 0.0299 Etan – Adal 12,485 322 1.1222 0.0253 Et+M – Ad+M 12,802 323 0.8242 0.0263 Ad+M – In+M 20 289 0.2417 0.0213 Et+M – In+M 12,822 316 1.0659 0.0262 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 40,800 39,200 to 42,500 Etan – Base 23,900 23,300 to 24,500 Ad+M – Base 30,200 29,300 to 31,300 Et+M – Base 24,100 23,500 to 24,700 In+M – Base 38,400 36,900 to 39,900 Adal – Ad+M Adal+MTX more effective than Adal alone; diff. cost not significant Et+M – Etan Comparison is inconclusive Etan – Adal 11,100 10,400 to 11,900 Et+M – Ad+M 15,500 14,400 to 16,900 Ad+M – In+M Adal+MTX more effective than Infl+MTX; diff. cost not significant Et+M – In+M 12,000 11,200 to 12,900 Variation 15 In this variation, short-term quitters on TNF inhibitors were increased by 50% compared to <strong>the</strong> base case. TABLE 150 Variation 15: TNF inhibitors first (400,000 patients) Option Cost (£) QSE QALYs QSE Adal 48,439 51 8.9461 0.0084 Etan 63,188 62 9.2858 0.0087 Adal+MTX 48,589 52 8.4953 0.0080 Etan+MTX 63,452 63 8.9254 0.0085 Infl+MTX 47,964 50 8.3522 0.0080 Base 15,293 10 8.2891 0.0079 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 33,146 50 0.6569 0.0085 Etan – Base 47,895 61 0.9967 0.0087 Ad+M – Base 33,296 51 0.2062 0.0083 Et+M – Base 48,159 61 0.6362 0.0086 In+M – Base 32,670 49 0.0631 0.0083 Ad+M – Adal 150 70 –0.4507 0.0085 Et+M – Etan 264 83 –0.3604 0.0090 continued
TABLE 150 Variation 15: TNF inhibitors first (400,000 patients) (cont’d) © Queen’s Printer and Controller <strong>of</strong> HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 42 Etan – Adal 14,749 77 0.3398 0.0088 Et+M – Ad+M 14,862 78 0.4301 0.0086 Ad+M – In+M 626 69 0.1431 0.0083 Et+M – In+M 15,488 76 0.5732 0.0086 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 50,500 49,200 to 51,800 Etan – Base 48,100 47,200 to 48,900 Ad+M – Base 161,000 149,000 to 176,000 Et+M – Base 75,700 73,700 to 77,800 In+M – Base 518,000 410,000 to 703,000 Ad+M – Adal Adal alone dominates Adal+MTX Et+M – Etan Etan alone dominates Etan+MTX Etan – Adal 43,400 41,200 to 45,800 Et+M – Ad+M 34,600 33,200 to 36,100 Ad+M – In+M 4,370 3,280 to 5,460 Et+M – In+M 27,000 26,200 to 27,900 TABLE 151 Variation 15: TNF inhibitors third (early RA values) (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 47,414 99 6.3210 0.0149 Etan 60,282 119 6.8437 0.0159 Adal+MTX 47,500 99 6.4689 0.0149 Etan+MTX 60,789 120 6.9720 0.0159 Infl+MTX 47,191 95 6.4248 0.0148 Base 16,484 23 5.4070 0.0137 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 30,930 97 0.9140 0.0148 Etan – Base 43,798 116 1.4367 0.0156 Ad+M – Base 31,017 97 1.0619 0.0149 Et+M – Base 44,305 117 1.5650 0.0158 In+M – Base 30,708 93 1.0178 0.0147 Ad+M – Adal 86 132 0.1479 0.0155 Et+M – Etan 507 155 0.1283 0.0169 Etan – Adal 12,868 145 0.5228 0.0162 Et+M – Ad+M 13,288 145 0.5031 0.0163 Ad+M – In+M 309 129 0.0441 0.0115 Et+M – In+M 13,597 143 0.5472 0.0162 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 33,800 32,800 to 35,000 Etan – Base 30,500 29,800 to 31,200 Ad+M – Base 29,200 28,400 to 30,100 Et+M – Base 28,300 27,700 to 28,900 In+M – Base 30,200 29,300 to 31,100 Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant Et+M – Etan 3,950 1,310 to 6,590 Etan – Adal 24,600 23,100 to 26,300 Et+M – Ad+M 26,400 24,700 to 28,400 Ad+M – In+M 7,010 Dominates to 14,700 Et+M – In+M 24,900 23,400 to 26,500 217
Page 1 and 2:
A systematic review of the effectiv
Page 3 and 4:
A systematic review of the effectiv
Page 5 and 6:
Objectives: This report reviews the
Page 7:
Glossary and list of abbreviations
Page 10 and 11:
viii Glossary and list of abbreviat
Page 13 and 14:
Background Rheumatoid arthritis (RA
Page 15:
increased risk of serious infection
Page 19 and 20:
Summary RA is a common, chronic, in
Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
Page 23 and 24:
Assessment of response to DMARDs Re
Page 25 and 26:
combination with methotrexate or al
Page 27:
disease between clinic appointments
Page 30 and 31:
14 Effectiveness in juvenile arthri
Page 32 and 33:
16 Effectiveness adalimumab plus me
Page 34 and 35:
18 Effectiveness Monoclonal Antibod
Page 36 and 37:
20 TABLE 1 Description of included
Page 38 and 39:
22 TABLE 2 Quality of included RCTs
Page 40 and 41:
24 Effectiveness change in modified
Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
Page 44 and 45:
28 Effectiveness Review: Adalimumab
Page 46 and 47:
30 Effectiveness Review: Adalimumab
Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
Page 54 and 55:
38 Effectiveness etanercept trials.
Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
Page 58 and 59:
42 Effectiveness Review: Etanercept
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
Page 72 and 73:
56 TABLE 12 Description of included
Page 74 and 75:
58 TABLE 13 Quality of included RCT
Page 76 and 77:
60 Effectiveness per week and escal
Page 78 and 79:
62 Effectiveness significant advant
Page 80 and 81:
64 Effectiveness Review: Infliximab
Page 82 and 83:
66 Effectiveness Review: Infliximab
Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
Page 89 and 90:
Summary of review of existing econo
Page 91 and 92:
TABLE 20 Summary of published ICERs
Page 93 and 94:
TABLE 21 Published etanercept econo
Page 95 and 96:
TABLE 23 Published economic analyse
Page 97 and 98:
TABLE 25 Treatment sequences: adali
Page 99 and 100:
management of RA, i.e. 1st and 2nd
Page 101 and 102:
To estimate the long-term consequen
Page 103 and 104:
TABLE 32 TNF inhibitors as last act
Page 105 and 106:
TABLE 34 Basic structure of the mod
Page 107 and 108:
een quit on grounds of toxicity, ad
Page 109 and 110:
TABLE 39 Strategy set: adalimumab a
Page 111 and 112:
TABLE 43 Beta distributions for HAQ
Page 113 and 114:
TABLE 44 Early cessation of DMARDs:
Page 115 and 116:
TABLE 46 Unit costs for tests and v
Page 117 and 118:
following properties, according to
Page 119 and 120:
TABLE 52 Base case: TNF inhibitors
Page 121 and 122:
TABLE 54 Base case: TNF inhibitors
Page 123 and 124:
TABLE 59 Third TNF inhibitor follow
Page 125 and 126:
TABLE 65 Sensitivity analyses: TNF
Page 127 and 128:
TABLE 67 Sensitivity analyses: TNF
Page 129:
The substantial economic impact of
Page 133 and 134:
Summary Effectiveness: principal fi
Page 135 and 136:
inhibitors, although the incrementa
Page 137 and 138:
introduce bias which generally exag
Page 139:
Adalimumab, etanercept and inflixim
Page 143 and 144:
1. Jobanputra P, Barton P, Bryan S,
Page 145 and 146:
46. Young A, Dixey J, Cox N, Davies
Page 147 and 148:
tumor necrosis factor therapy in th
Page 149 and 150:
arthritis: a 12-week, double-blind,
Page 151 and 152:
171. Geborek P, Crnkic M, Petersson
Page 153 and 154:
216. Schotte H, Willeke P, Mickholz
Page 155 and 156:
The Health Assessment Questionnaire
Page 157 and 158:
Cochrane Library (CENTRAL) 2005 Iss
Page 159 and 160:
Appendix 3 © Queen’s Printer and
Page 161:
TABLE 69 Studies excluded from clin
Page 164 and 165:
148 Appendix 4 TABLE 71 Meta-analys
Page 166 and 167:
150 Appendix 4 TABLE 73 Meta-analys
Page 168 and 169:
152 Appendix 4 Infliximab versus pl
Page 170 and 171:
154 Appendix 4 Infliximab plus MTX
Page 173:
Ovid MEDLINE(R) 1966 to February we
Page 177 and 178:
Appendix 8 © Queen’s Printer and
Page 179 and 180:
TABLE 79 Wong et al., 2002 161 © Q
Page 181 and 182: TABLE 80 Kobelt et al., 2003 162 (c
Page 183 and 184: TABLE 82 Brennan et al., 2004 160
Page 185 and 186: TABLE 83 Kobelt et al., 2004 163 (c
Page 187 and 188: TABLE 85 Bansback et al., 2005 166
Page 189: TABLE 86 Kobelt et al., 2005 167 (c
Page 192 and 193: 176 Appendix 9 TABLE 89 Strategy se
Page 195 and 196: Extensive sensitivity analysis was
Page 197 and 198: TABLE 96 Variation 1: TNF inhibitor
Page 199 and 200: TABLE 99 Variation 2: TNF inhibitor
Page 201 and 202: TABLE 102 Variation 3: TNF inhibito
Page 221 and 222: TABLE 132 Variation 10: TNF inhibit
Page 231: TABLE 147 Variation 14: TNF inhibit
Page 243: TABLE 165 Variation 18: TNF inhibit
Page 247 and 248: Volume 1, 1997 No. 1 Home parentera
Page 249 and 250: No. 3 Screening for sickle cell dis
Page 251 and 252: No. 25 A rapid and systematic revie
Page 253 and 254: No. 11 First and second trimester a
Page 255 and 256: No. 23 Clinical effectiveness and c
Page 257 and 258: No. 28 Outcomes of electrically sti
Page 259: No. 28 Adefovir dipivoxil and pegyl
Page 262 and 263: 246 Health Technology Assessment Pr
Page 264: 248 Health Technology Assessment Pr
show all

A systematic review of the effectiveness of adalimumab

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?